Sudeep Pharma Limited: insider trading, SAST and pledges

No insider-trading filing for this company in the last two years.

FiledAcquirerDirectionModeAcquiredSoldHolding afterPromoter
29 Jul 2026Nuvama Crossover Opportunites Fund-Series III
Reg29(1)
Acquisition Preferential Allotment 9,451,295
8.40%
— 8.40% No
29 Jul 2026Nuvama Crossover Opportunites Fund-Series III
Reg29(2)
Sale Open Market — 2,668,118
2.40%
6.00% No
Page 1 of 1

Disclosures are shown as filed with the exchanges; Tradinity does not verify them. Nothing here is investment advice.